324 related articles for article (PubMed ID: 19278968)
1. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
Kröger N; Brand R; van Biezen A; Zander A; Dierlamm J; Niederwieser D; Devergie A; Ruutu T; Cornish J; Ljungman P; Gratwohl A; Cordonnier C; Beelen D; Deconinck E; Symeonidis A; de Witte T;
Haematologica; 2009 Apr; 94(4):542-9. PubMed ID: 19278968
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
3. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
4. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
de Witte T; Hagemeijer A; Suciu S; Belhabri A; Delforge M; Kobbe G; Selleslag D; Schouten HC; Ferrant A; Biersack H; Amadori S; Muus P; Jansen JH; Hellström-Lindberg E; Kovacsovics T; Wijermans P; Ossenkoppele G; Gratwohl A; Marie JP; Willemze R
Haematologica; 2010 Oct; 95(10):1754-61. PubMed ID: 20494931
[TBL] [Abstract][Full Text] [Related]
5. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.
Chang C; Storer BE; Scott BL; Bryant EM; Shulman HM; Flowers ME; Sandmaier BM; Witherspoon RP; Nash RA; Sanders JE; Bedalov A; Hansen JA; Clurman BE; Storb R; Appelbaum FR; Deeg HJ
Blood; 2007 Aug; 110(4):1379-87. PubMed ID: 17488876
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
Litzow MR; Tarima S; Pérez WS; Bolwell BJ; Cairo MS; Camitta BM; Cutler CS; de Lima M; Dipersio JF; Gale RP; Keating A; Lazarus HM; Luger S; Marks DI; Maziarz RT; McCarthy PL; Pasquini MC; Phillips GL; Rizzo JD; Sierra J; Tallman MS; Weisdorf DJ
Blood; 2010 Mar; 115(9):1850-7. PubMed ID: 20032503
[TBL] [Abstract][Full Text] [Related]
8. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
[TBL] [Abstract][Full Text] [Related]
9. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.
Yokoyama H; Mori S; Kobayashi Y; Kurosawa S; Saito B; Fuji S; Maruyama D; Azuma T; Kim SW; Watanabe T; Tanosaki R; Tobinai K; Takaue Y; Fukuda T
Int J Hematol; 2010 Sep; 92(2):334-41. PubMed ID: 20680530
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
13. ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission.
Damiani D; Tiribelli M; Geromin A; Cerno M; Zanini F; Michelutti A; Fanin R
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1621-1626. PubMed ID: 27178373
[TBL] [Abstract][Full Text] [Related]
14. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract][Full Text] [Related]
17. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
18. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
